Gilead Sciences agreed to pay $202 million to settle a whistleblower lawsuit accusing the drugmaker of civil fraud for paying ...

A New York doctor who treated HIV and AIDS patients sued Gilead for violating the False Claims Act with payments to doctors ...

Shares of Gilead Sciences Inc. GILD shed 2.00% to $104.21 Tuesday, on what proved to be an all-around positive trading ...

Gilead Sciences has reached a $202 million settlement to resolve a civil fraud lawsuit accusing the company of paying ...

[CNBC] Gilead Sciences agrees to pay $202 million to settle claims of kickbacks to doctors for HIV drug prescriptions ...

Gilead Sciences on Thursday reported a first-quarter profit, but revenue was flat, as higher sales of drugs for HIV and liver ...

(Nasdaq: GILD) announced today its first quarter 2025 results of operations. "Gilead had a strong start to the year driven by ...

The company's first-quarter revenue slipped 0.3% year-over-year to $6.67 billion, while analysts surveyed by Visible Alpha ...

As the Trump administration stares down diversity programs, this big Peninsula employer is highlighting its efforts.

Gilead (GILD) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Over the years, a host of large drugmakers have inked settlements with the federal authorities to resolve allegations that ...

The OHSAA announced expanded divisions for cross country along with divisional breakdowns for other fall sports for the 2025 ...